- Home
- APPS vs CVRX Comparison
APPS vs CVRX Comparison
Compare APPS & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APPS
- CVRX
- Stock Information
- Founded
- APPS 2007
- CVRX 2000
- Country
- APPS United States
- CVRX United States
- Employees
- APPS N/A
- CVRX N/A
- Industry
- APPS Multi-Sector Companies
- CVRX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- APPS Miscellaneous
- CVRX Health Care
- Exchange
- APPS Nasdaq
- CVRX Nasdaq
- Market Cap
- APPS 243.8M
- CVRX 181.5M
- IPO Year
- APPS N/A
- CVRX 2021
- Fundamental
- Price
- APPS $4.62
- CVRX $6.35
- Analyst Decision
- APPS Hold
- CVRX Buy
- Analyst Count
- APPS 3
- CVRX 7
- Target Price
- APPS $2.33
- CVRX $14.50
- AVG Volume (30 Days)
- APPS 3.3M
- CVRX 516.1K
- Earning Date
- APPS 06-10-2025
- CVRX 05-08-2025
- Dividend Yield
- APPS N/A
- CVRX N/A
- EPS Growth
- APPS N/A
- CVRX N/A
- EPS
- APPS N/A
- CVRX N/A
- Revenue
- APPS $483,577,000.00
- CVRX $52,870,000.00
- Revenue This Year
- APPS N/A
- CVRX $13.92
- Revenue Next Year
- APPS $6.49
- CVRX $19.89
- P/E Ratio
- APPS N/A
- CVRX N/A
- Revenue Growth
- APPS N/A
- CVRX 25.62
- 52 Week Low
- APPS $1.18
- CVRX $4.30
- 52 Week High
- APPS $6.86
- CVRX $18.55
- Technical
- Relative Strength Index (RSI)
- APPS 61.30
- CVRX 44.02
- Support Level
- APPS $4.31
- CVRX $6.08
- Resistance Level
- APPS $5.19
- CVRX $7.17
- Average True Range (ATR)
- APPS 0.38
- CVRX 0.57
- MACD
- APPS -0.01
- CVRX 0.14
- Stochastic Oscillator
- APPS 49.56
- CVRX 65.03
About APPS Digital Turbine Inc.
Digital Turbine Inc is an independent mobile growth platform. It offers end-to-end products and solutions to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. Its operating segments are On Device Solutions and App Growth Platform.
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.